Lymphoma Clinical Trials in Philadelphia

Showing 521-540 of 599 trials

Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL

NCT00655837

The purpose of this study is to determine safety and tolerability of combination therapy of SGN-40 with gemcitabine and rituximab for the treatment of lymphoma. This study is also intended to estimate how well your disease responds to this treatment.

Lymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin

Seagen Inc.33 participantsStarted Apr 2008

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • Aurora, Colorado, United States +6 more locations

COMPLETEDPhase 1< 1 mile

Cardiac Safety Study of Brentuximab Vedotin (SGN-35)

NCT01026233

The purpose of this study is to evaluate cardiac safety of brentuximab vedotin (SGN-35) in patients with CD30-positive cancers. The study will assess electrical activity of the heart before and after brentuximab vedotin administration. Patients who have stable or improving disease may receive up to 1 year of brentuximab vedotin treatment.

Disease, HodgkinLymphoma, Large-Cell, AnaplasticLymphoma, Non-Hodgkin

Seagen Inc.52 participantsStarted Jan 2010

Birmingham, Alabama, United States • Duarte, California, United States • Stanford, California, United States +6 more locations

Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL

Cardiac Safety Study of Brentuximab Vedotin (SGN-35)

Lymphoma Trials in Other Cities

Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease

Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients

Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease

Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy

CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma

GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma

Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer

Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma

Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)

S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma

An Observational Study of Lymphoma in Patients With Rheumatoid Arthritis or Crohn's Disease.

CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)

Other Conditions in Philadelphia